Phenotypic expression of a family with multiple endocrine neoplasia type 2A due to a RET mutation at codon 618

被引:21
作者
Lindskog, S [1 ]
Nilsson, O
Jansson, S
Nilsson, B
Illerskog, AC
Ysander, L
Ahlman, H
Tisell, LE
机构
[1] Varberg Hosp, Dept Surg, S-43281 Varberg, Sweden
[2] Varberg Hosp, Dept Med, S-43281 Varberg, Sweden
[3] Sahlgrens Univ Hosp, Dept Surg, Lundberg Lab Canc Res, S-41345 Gothenburg, Sweden
[4] Sahlgrens Univ Hosp, Dept Pathol, Lundberg Lab Canc Res, S-41345 Gothenburg, Sweden
关键词
D O I
10.1002/bjs.4457
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Multiple endocrine neoplasia type 2A (MEN2A) is caused by missense mutations in the RET proto-oncogene on chromosome 10. This paper reports the phenotypic expression of a family with MEN2A, in which serine substitutes for cysteine at codon 618 in exon 10 of the RET gene. It was first claimed that medullary thyroid cancer (MTC) with this rare mutation led to mild disease; this has recently been updated to intermediate-high risk, based on stratified genetic information. Methods: The family was mapped over six generations. In 1971 family members were invited to join a screening programme. Genetic testing was started in 1994. Results: Twenty-two individuals with MTC were identified, 16 by the screening programme. One screened patient had a phaeochromocytoma and four had hyperparathyroidism. At surgery for MTC 12 patients had local tumour metastases and two young patients also had liver metastases. No screened patient died from MTC during a mean observation time of 19 years. Six other family members were diagnosed with MTC by signs and symptoms, five of whom died from MTC. Conclusion: Because of the great interindividual differences in tumour aggressiveness within the family it is impossible to predict whether an individual gene carrier will have an aggressive MTC or not. This unpredictability is an additional argument, besides those obtained in stratified genetic studies, for operating on gene carriers at young age.
引用
收藏
页码:713 / 718
页数:6
相关论文
共 24 条
[1]   INCIDENCE OF SPORADIC AND FAMILIAL MEDULLARY-THYROID CARCINOMA IN SWEDEN 1959 THROUGH 1981 - A NATIONWIDE STUDY IN 126 PATIENTS [J].
BERGHOLM, U ;
ADAMI, HO ;
TELENIUSBERG, M ;
JOHANSSON, H ;
WILANDER, E .
ACTA ONCOLOGICA, 1990, 29 (01) :9-15
[2]   Guidelines for diagnosis and therapy of MEN type 1 and type 2 [J].
Brandi, ML ;
Gagel, RF ;
Angeli, A ;
Bilezikian, JP ;
Beck-Peccoz, P ;
Bordi, C ;
Conte-Devolx, B ;
Falchetti, A ;
Gheri, RG ;
Libroia, A ;
Lips, CJM ;
Lombardi, G ;
Mannelli, M ;
Pacini, F ;
Pondder, BAJ ;
Raue, F ;
Skogseid, B ;
Tamburrano, G ;
Thakker, RV ;
Thompson, NW ;
Tomassetti, P ;
Tonelli, F ;
Wells, SA ;
Marx, SJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12) :5658-5671
[3]   SINGLE MISSENSE MUTATION IN THE TYROSINE KINASE CATALYTIC DOMAIN OF THE RET PROTOONCOGENE IS ASSOCIATED WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B [J].
CARLSON, KM ;
DOU, SS ;
CHI, D ;
SCAVARDA, N ;
TOSHIMA, K ;
JACKSON, CE ;
WELLS, SA ;
GOODFELLOW, PJ ;
DONISKELLER, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) :1579-1583
[4]   MUTATIONS IN THE RET PROTOONCOGENE ARE ASSOCIATED WITH MEN 2A AND FMTC [J].
DONISKELLER, H ;
DOU, SS ;
CHI, D ;
CARLSON, KM ;
TOSHIMA, K ;
LAIRMORE, TC ;
HOWE, JR ;
MOLEY, JF ;
GOODFELLOW, P ;
WELLS, SA .
HUMAN MOLECULAR GENETICS, 1993, 2 (07) :851-856
[5]   Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan [J].
Egawa, S ;
Futami, H ;
Takasaki, K ;
Iihara, M ;
Okamoto, T ;
Kanbe, M ;
Ohi, T ;
Saio, Y ;
Miyauchi, A ;
Takiyama, Y ;
Koga, M ;
Miyanaga, K ;
Inoue, K ;
Mitsuyama, S ;
Nomura, Y ;
Takei, H ;
Mugiya, S ;
Ishida, O ;
Zeze, F ;
Shakutsui, S ;
Inoue, H ;
Oya, H ;
Yoshimura, A ;
Ishizuka, S ;
Tsujino, T ;
Obara, T ;
Yamaguchi, K .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1998, 28 (10) :590-596
[6]   The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2 - International RET mutation consortium analysis [J].
Eng, C ;
Clayton, D ;
Schuffenecker, I ;
Lenoir, G ;
Cote, G ;
Gagel, RF ;
vanAmstel, HKP ;
Lips, CJM ;
Nishisho, I ;
Takai, SI ;
Marsh, DJ ;
Robinson, BG ;
FrankRaue, K ;
Raue, F ;
Xue, FY ;
Noll, WW ;
Romei, C ;
Pacini, F ;
Fink, M ;
Niederle, B ;
Zedenius, J ;
Nordenskjold, M ;
Komminoth, P ;
Hendy, GN ;
Gharib, H ;
Thibodeau, SN ;
Lacroix, A ;
Frilling, A ;
Ponder, BAJ ;
Mulligan, LM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (19) :1575-1579
[7]   THE CLINICAL OUTCOME OF PROSPECTIVE SCREENING FOR MULTIPLE ENDOCRINE NEOPLASIA TYPE-2A - AN 18-YEAR EXPERIENCE [J].
GAGEL, RF ;
TASHJIAN, AH ;
CUMMINGS, T ;
PAPATHANASOPOULOS, N ;
KAPLAN, MM ;
DELELLIS, RA ;
WOLFE, HJ ;
REICHLIN, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (08) :478-484
[8]  
HERMANEK P, 1992, UICC TNM CLASSIFICAT, P35
[9]  
KIKUMORI T, 2001, SURG ENDOCRINOLOGY, P531
[10]   CLINICAL SCREENING AS COMPARED WITH DNA ANALYSIS IN FAMILIES WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A [J].
LIPS, CJM ;
LANDSVATER, RM ;
HOPPENER, JWM ;
GEERDINK, RA ;
BLIJHAM, G ;
VANVEEN, JMJS ;
VANGILS, APG ;
DEWIT, MJ ;
ZEWALD, RA ;
BERENDS, MJH ;
BEEMER, FA ;
BROUWERSSMALBRAAK, J ;
JANSEN, RPM ;
VANAMSTEL, HKP ;
VANVROONHOVEN, TJM ;
VROOM, TM .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (13) :828-835